JP5284092B2 - 腸溶コーティングに適したパンクレアチンマイクロペレットコア - Google Patents

腸溶コーティングに適したパンクレアチンマイクロペレットコア Download PDF

Info

Publication number
JP5284092B2
JP5284092B2 JP2008526493A JP2008526493A JP5284092B2 JP 5284092 B2 JP5284092 B2 JP 5284092B2 JP 2008526493 A JP2008526493 A JP 2008526493A JP 2008526493 A JP2008526493 A JP 2008526493A JP 5284092 B2 JP5284092 B2 JP 5284092B2
Authority
JP
Japan
Prior art keywords
pancreatin
micropellet
pancreatine
enzyme
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2008526493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504710A5 (enExample
JP2009504710A (ja
Inventor
シュリーオウト ゲオルゲ
ケルン クラウス−ユルゲン
チェズニー フリトヨーフ
オンケン イェンス
リュージンク ギドー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories GmbH
Original Assignee
Abbott Laboratories GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5284092(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories GmbH filed Critical Abbott Laboratories GmbH
Publication of JP2009504710A publication Critical patent/JP2009504710A/ja
Publication of JP2009504710A5 publication Critical patent/JP2009504710A5/ja
Application granted granted Critical
Publication of JP5284092B2 publication Critical patent/JP5284092B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Finger-Pressure Massage (AREA)
JP2008526493A 2005-08-15 2006-08-15 腸溶コーティングに適したパンクレアチンマイクロペレットコア Expired - Lifetime JP5284092B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70852605P 2005-08-15 2005-08-15
EP05107474.8 2005-08-15
US60/708,526 2005-08-15
EP05107474 2005-08-15
PCT/EP2006/065313 WO2007020260A2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Publications (3)

Publication Number Publication Date
JP2009504710A JP2009504710A (ja) 2009-02-05
JP2009504710A5 JP2009504710A5 (enExample) 2009-07-09
JP5284092B2 true JP5284092B2 (ja) 2013-09-11

Family

ID=37401623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008526493A Expired - Lifetime JP5284092B2 (ja) 2005-08-15 2006-08-15 腸溶コーティングに適したパンクレアチンマイクロペレットコア

Country Status (15)

Country Link
EP (1) EP1931317B1 (enExample)
JP (1) JP5284092B2 (enExample)
KR (1) KR101302841B1 (enExample)
AT (1) ATE418329T1 (enExample)
AU (1) AU2006281415B2 (enExample)
CA (1) CA2619477C (enExample)
DE (1) DE602006004471D1 (enExample)
ES (1) ES2320174T3 (enExample)
IL (1) IL189457A (enExample)
MX (1) MX2008001557A (enExample)
NO (1) NO20081379L (enExample)
PL (1) PL1931317T3 (enExample)
PT (1) PT1931317E (enExample)
RU (1) RU2408364C2 (enExample)
WO (1) WO2007020260A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
PL2278002T3 (pl) 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
PT2079445E (pt) 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
BRPI0906439A2 (pt) * 2008-01-03 2018-12-04 Abbott Products Gmbh composições farmacêuticas que compreendem grânulos de lipase microbiana purificada e métodos para a prevenção ou tratamento de distúrbios digestivos
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EA029101B1 (ru) 2010-10-01 2018-02-28 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3639846B1 (en) 2013-08-09 2022-09-28 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
EP3157568A1 (en) 2014-06-19 2017-04-26 Aptalis Pharma Limited Methods for removing viral contaminants from pancreatic extracts
CN114917328B (zh) 2014-11-05 2025-06-20 雅培制药股份有限公司 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
RU2706003C1 (ru) * 2019-09-09 2019-11-13 Акционерное общество "АВВА РУС" Микрогранулы, содержащие панкреатин
MX2022014395A (es) * 2020-06-10 2022-12-02 Kusum Healthcare Pvt Ltd Composicion farmaceutica de pancreatina.
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR102950325B1 (ko) 2024-01-26 2026-04-08 황준영 판크레아틴 함유 속방성 장용코팅 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
BR0009012A (pt) * 1999-03-17 2001-12-26 Solvay Pharm Gmbh Medicamento para o tratamento de diabete
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
WO2007020260A3 (en) 2007-05-10
AU2006281415A1 (en) 2007-02-22
DE602006004471D1 (de) 2009-02-05
RU2008109651A (ru) 2009-09-27
AU2006281415B2 (en) 2012-01-19
ES2320174T3 (es) 2009-05-19
PL1931317T3 (pl) 2009-06-30
IL189457A0 (en) 2008-06-05
EP1931317A2 (en) 2008-06-18
PT1931317E (pt) 2009-02-02
MX2008001557A (es) 2008-02-15
CA2619477A1 (en) 2007-02-22
KR20080034516A (ko) 2008-04-21
EP1931317B1 (en) 2008-12-24
KR101302841B1 (ko) 2013-09-02
JP2009504710A (ja) 2009-02-05
HK1119559A1 (en) 2009-03-13
RU2408364C2 (ru) 2011-01-10
IL189457A (en) 2014-05-28
WO2007020260A2 (en) 2007-02-22
ATE418329T1 (de) 2009-01-15
CA2619477C (en) 2015-05-26
NO20081379L (no) 2008-05-14

Similar Documents

Publication Publication Date Title
JP2009504710A (ja) 腸溶コーティングに適したパンクレアチンマイクロペレットコア
US20240148660A1 (en) Process for the manufacture and use of pancreatin micropellet cores
US20210353722A1 (en) Controlled release pharmaceutical compositions for acid-labile drugs
DK1931316T4 (en) Controlled-release pharmaceutical compositions for use in acid-labile drugs
NZ565959A (en) Pancreatin micropellet cores suitable for enteric coating
US20240131125A1 (en) Controlled release pharmaceutical compositions for acid-labile drugs
KR101344546B1 (ko) 산 불안정성 약제를 위한 조절방출 약제학적 조성물
HK1119559B (en) Pancreatin micropellet cores suitable for enteric coating
WO2021250700A1 (en) Pharmaceutical composition of pancreatin

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090520

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120515

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121213

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130529

R150 Certificate of patent or registration of utility model

Ref document number: 5284092

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250